Patent application number | Description | Published |
20080274151 | COSMETIC COMPOSITION - A cosmetic composition comprising a cosmetic base selected from the group consisting of liquid base, paste base and powder base, a perfume ingredient, and polyamide particles wherein the polyamide particles comprise at least either of the porous polyamide particles of the following (1) and (2) shows satisfactory shape retention on human skin, excellent light-scattering properties to diminish abnormal light reflection on human skin surface, and excellent oil-absorbing properties to effectively absorb lipid oozing from human body when it is applied to human skin: (1) spherical porous polyamide particles having a number average particle diameter of 1 to 30 μm, a BET specific surface area of 5 m | 11-06-2008 |
20130038822 | POLYAMIDE MICROPARTICLES, MANUFACTURING METHOD THEREFOR, OPTICAL FILM USING SAID POLYAMIDE MICROPARTICLES, AND LIQUID CRYSTAL DISPLAY DEVICE - Disclosed are polyamide microparticles, a manufacturing method therefor, an optical film, and a liquid crystal display device using the polyamide microparticles, whereby polarized light can be efficiently converted to non-polarized light that is close to natural light, without accompanying a change in color, and light from a light source can be evenly diffused. The disclosed polyamide microparticles are characterized by including a spherocrystal structure and exhibiting a crystallite size of at least 12 nm, as measured by wide-angle X ray diffraction, and a crystallinity of at least 50%, as measured by DSC. The disclosed optical film is characterized by having a resin layer that contains the aforementioned polyamide microparticles. The disclosed liquid crystal display device is provided with a light-source device, a rear polarizer, liquid crystal cells, and a front polarizer, and is characterized by having the aforementioned optical film between the light-source device and either the front surface of the front polarizer or the rear surface of the rear polarizer. | 02-14-2013 |
Patent application number | Description | Published |
20100130492 | MORPHOLINOPURINE DERIVATIVES - There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: | 05-27-2010 |
20120071476 | MORPHOLINOPURINE DERIVATIVES - There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: | 03-22-2012 |
20120108582 | Fused substituted aminopyrrolidine derivative - A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. | 05-03-2012 |
20130029977 | Fused substituted aminopyrrolidine derivative - A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. | 01-31-2013 |
Patent application number | Description | Published |
20090130604 | Solution for immersion exposure and immersion exposure method - The object is to resolve a finer pattern with a narrower line/space width by immersion lithography technology in the manufacture of a semiconductor or the like. A liquid for use in immersion exposure includes a saturated hydrocarbon compound as a main component, wherein the content of an impurity or impurities having an unsaturated bond or a heteroatom in its structure is respectively as follows: (i) 2 μg/mL or less in total for a compound having a conjugated unsaturated bond; (ii) 30 μg/mL or less in total for a compound having no conjugated unsaturated bond but having a non-conjugated unsaturated bond; (iii) 15 μg/mL or less in total for amines having no unsaturated bond; and (iv) 100 μg/mL or less in total for a heterocyclic compound, alcohols, ethers and a halogen-containing compound, other than above compounds (i) to (iii). | 05-21-2009 |
20090273768 | Liquid for immersion exposure, method of purifying the same,and immersion exposure method - A saturated hydrocarbon compound is brought into contact at least with a first adsorbent and a second adsorbent to obtain a liquid for immersion exposure containing the saturated hydrocarbon compound with a purity of 99.5 wt % or more. | 11-05-2009 |
20100029804 | HARDCOAT COMPOSITION - A hard coating composition including at least the following components (A) to (E): Component (A): A poly(methyl)glycidyl ether compound derived from a chain aliphatic polyol or a chain aliphatic polyether polyol, which may or may not contain a hydroxyl group, Component (B): A silsesquioxane compound containing a cationic polymerizable group, Component (C): A silicate compound, Component (D): A silane compound containing a cationic polymerizable group, or a partial condensed compound thereof, or a mixture thereof, and Component (E): A cationic photopolymerization initiator, wherein the composition includes 5 to 40 parts by weight of the component (A), 60 to 95 parts by weight of the total of the components (B), (C) and (D), and 0.1 to 10 parts by weight of the component (E), each based on 100 parts by weight of the total of the components (A) to (D). | 02-04-2010 |
20110118361 | NOVEL POLYMER PARTICLES AND USE THEREOF - Provided are polymer particles composed of a terminally branched copolymer represented by the following general formula (1) and having a number average molecular weight of not more than 2.5×10 | 05-19-2011 |
20110318249 | NOVEL POROUS METAL OXIDE, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME - Disclosed is a porous metal oxide obtained by subjecting metal alkoxide and/or a partially hydrolyzed condensate of the metal alkoxide to a sol-gel reaction in the presence of terminally branched copolymer particles represented by the following general formula (1) and having a number average molecular weight of not more than 2.5×10 | 12-29-2011 |
Patent application number | Description | Published |
20100014178 | Absorption type multi-layer film ND filter - In an absorption type multi-layer film ND filter having a thin substrate and provided thereon first and second absorption type multi-layer films which attenuate transmitted light, the first and second absorption type multi-layer films are constituted of multi-layer films each consisting essentially of dielectric layers formed of SiO | 01-21-2010 |
20120325310 | LAMINATE, METHOD FOR PRODUCING SAME, AND FUNCTIONAL ELEMENT USING SAME - Provided is a laminate which includes a transparent conductive film layer that is composed of an oxide thin film mainly composed of titanium oxide and contains an additional element such as niobium, and also contains an anatase phase having more excellent crystallinity and further has high refractive index and low resistivity by forming an optimal buffer layer on the substrate. Also provided are: a semiconductor light emitting element which comprises the laminate; and a functional element such as a solar cell, which includes the laminate. | 12-27-2012 |
20150206615 | OXIDE SINTERED BODY AND TABLET OBTAINED BY PROCESSING SAME - A tablet for ion plating which allows high speed formation of transparent conductive films suitable for solar cells and allows continuous film formation without causing cracks, breakage or splashing. A sintered oxide includes indium oxide as a main component and tin as an additive element, and having a tin content of 0.001 to 0.15 in terms of an atomic ratio of Sn/(In+Sn). The sintered oxide mainly includes crystal grains (A) having a tin content that is less than an average tin content of the sintered oxide and crystal grains (B) having a tin content that is at or above the average tin content of the sintered oxide, the difference in the average tin content between the crystal grains (B) and the crystal grains (A) being 0.015 or more in terms of the atomic ratio of Sn/(In+Sn), and has a density of 3.4 to 5.5 g/cm | 07-23-2015 |
Patent application number | Description | Published |
20110142813 | Use Of Anti-Cancer Cell Composition For Treatment Of Head And Neck Cancer, Which Is Intended To Be Administered To Nutrient Artery Of Tumor - To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition. | 06-16-2011 |
20120121503 | Inhibition Of CD69 For Treatment Of Inflammatory Conditions - A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical. | 05-17-2012 |
20130224111 | Inhibition Of CD69 For Treatment Of Inflammatory Conditions - A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical. | 08-29-2013 |
20130244259 | NOVEL TESTING METHOD AND TESTING REAGENT FOR ANGIITIS - [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. | 09-19-2013 |